Back to search results

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Abroad (travel likely)RecruitingPHASE3

Conditions

Alopecia Areata

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Nagoya City University Hospital /ID# 275409, Nagoya, Aichi-ken, Japan

  • Kurume University Hospital /ID# 275519, Kurume-shi, Fukuoka, Japan

  • Kanazawa Medical University Hospital /ID# 275521, Kahoku-gun, Ishikawa-ken, Japan

  • Nagomi Dermatology Clinic /ID# 275418, Ebina-shi, Kanagawa, Japan

  • Rifu Dermatology Allergy Clinic /ID# 274875, Miyagi-gun, Miyagi, Japan

  • Tohoku University Hospital /ID# 274931, Sendai, Miyagi, Japan

  • Niigata University Medical & Dental Hospital /ID# 274775, Niigata, Niigata, Japan

  • Shinsaibashi Inui Dermatology Clinic /ID# 274851, Osaka, Osaka, Japan

  • Osaka Metropolitan University Hospital /ID# 274956, Osaka, Osaka, Japan

  • Hamamatsu University Hospital /ID# 274639, Hamamatsu, Shizuoka, Japan

  • Kyorin University Hospital /ID# 274882, Mitaka-shi, Tokyo, Japan

  • Tokyo Medical University Hospital /ID# 274844, Shinjuku-ku, Tokyo, Japan

  • Keio University Hospital /ID# 275640, Shinjuku-ku, Tokyo, Japan

  • Yamaguchi University Hospital /ID# 274638, Ube, Yamaguchi, Japan

  • Juntendo Tokyo Koto Geriatric Medical Center /ID# 275424, Tokyo, Japan

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)